1. Search Result
Search Result
Results for "

Mitophagy

" in MedChemExpress (MCE) Product Catalog:

31

Inhibitors & Agonists

2

Screening Libraries

7

Natural
Products

3

Isotope-Labeled Compounds

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-115576
    P62-mediated mitophagy inducer
    3 Publications Verification

    PMI

    Mitophagy Autophagy Neurological Disease Cancer
    P62-mediated mitophagy inducer (PMI) is a P62-mediated mitophagy activator. P62-mediated mitophagy inducer activates mitochondrial autophagy without recruitment of Parkin or collapse of the mitochondrial membrane potential and remains active in cells lacking a fully functional PINK1/Parkin pathway. P62-mediated mitophagy inducer serves as a pharmacological tool to study the molecular mechanisms of mitosis, avoiding toxicity and some of the non-specific effects associated with the sudden dissipation of mitochondria lacking membrane potential .
    P62-mediated <em>mitophagy</em> inducer
  • HY-141659
    CMPD-39
    1 Publications Verification

    Deubiquitinase Cancer
    CMPD-39 is a selective USP30 inhibitor with an IC50 of 0.02 μM. CMPD-39 increases protein ubiquitination and accelerates mitophagy .
    CMPD-39
  • HY-152943

    EP-0035985

    Mitophagy Mitochondrial Metabolism Neurological Disease Cancer
    MTK458 is an orally active brain penetrant PINK1 activator. MTK458 binds to PINK1 and stabilizes an active heterocomplex, thereby increasing mitophagy. MTK458 can be used for research on Parkinson's disease .
    MTK458
  • HY-163172

    Others Neurological Disease
    Miro1 Reducer is a small molecule that can repair this defect of Miro1 in Parkinson's disease (PD) fibroblasts. Miro1 Reducer reduces the delayed mitophagy phenotype in PD fibroblasts. Miro1 Reducer reduces Miro1 protein levels in dose-dependent manner (IC50 = 7.8 mM) .
    Miro1 Reducer
  • HY-152265

    Mitophagy Neurological Disease
    PARL-IN-1 is a potent PARL inhibitor with an IC50 value of 28 nM. PARL-IN-1 inhibits PARL and leads to a robust activation of the PINK1/Parkin pathway. PARL-IN-1 promotes PINK1/Parkin-dependent mitophagy .
    PARL-IN-1
  • HY-147225

    AUTACs Mitophagy Neurological Disease Metabolic Disease Cancer
    TSPO Ligand-Linker Conjugates 1 contains a ligand for translocator protein (TSPO) and a linker, which is used for the synthesis of mitochondria-targeting autophagy-targeting chimera (AUTAC). AUTAC can bind the TSPO on the outer mitochondrial membrane (OMM) of mitochondria and degrades impaired mitochondria and proteins via mitophagy, and improves mitochondrial activity. TSPO Ligand-Linker Conjugates 1 can be used in mitochondrial dysfunction related research, including neurodegenerative diseases, cancer, and diabetes .
    TSPO Ligand-Linker Conjugates 1
  • HY-153089
    GSK3-IN-3
    1 Publications Verification

    GSK-3 Mitophagy Neurological Disease
    GSK3-IN-3 is a mitophagy inducer, inducing Parkin-dependent mitophagy. GSK3-IN-3 is also a GSK-3 inhibitor with an IC50 value of 3.01 μM. GSK3-IN-3 is non-ATP nor substrate competitive and is neuroprotective against 6-OHDA .
    GSK3-IN-3
  • HY-152943A

    (Rac)-EP-0035985

    Mitophagy Cancer
    (Rac)-MTK458 (compound 16) is an activator of mitophagy. EP-0035985 is the isomer of EP-0035985 .
    (Rac)-MTK458
  • HY-15886
    Mdivi-1
    120+ Cited Publications

    Mitochondrial division inhibitor 1

    Dynamin Mitophagy Autophagy Apoptosis Cancer
    Mdivi-1 is a selective dynamin-related protein 1 (Drp1) inhibitor. Mdivi-1 is a mitochondrial division/mitophagy inhibitor.
    Mdivi-1
  • HY-112438
    MF-094
    3 Publications Verification

    Deubiquitinase Cancer
    MF-094 is a potent and selective USP30 inhibitor with an IC50 of 120 nM. MF-094 increases protein ubiquitination and accelerates mitophagy .
    MF-094
  • HY-134640

    AUTACs Mitophagy Neurological Disease Cancer
    AUTAC4 is a mitochondria-targeting autophagy-targeting chimera (AUTAC). AUTAC4 downregulates cytosolic proteins and promotes targeted mitochondrial turnover via mitophagy .
    AUTAC4
  • HY-13417A
    AICAR phosphate
    110+ Cited Publications

    Acadesine phosphate; AICA Riboside phosphate

    AMPK Autophagy YAP Mitophagy Endogenous Metabolite Cancer
    AICAR phosphate (Acadesine phosphate) is an adenosine analog and a AMPK activator. AICAR phosphate regulates the glucose and lipid metabolism, and inhibits proinflammatory cytokines and iNOS production. AICAR phosphate is also an autophagy, YAP and mitophagy inhibitor .
    AICAR phosphate
  • HY-13417
    AICAR
    110+ Cited Publications

    Acadesine; AICA Riboside

    AMPK Autophagy YAP Mitophagy Endogenous Metabolite Cancer
    AICAR (Acadesine) is an adenosine analog and a AMPK activator. AICAR regulates the glucose and lipid metabolism, and inhibits proinflammatory cytokines and iNOS production. AICAR is also an autophagy, YAP and mitophagy inhibitor .
    AICAR
  • HY-12031A
    U0126
    320+ Cited Publications

    MEK Autophagy Mitophagy Influenza Virus Cancer
    U0126 is a potent, non-ATP competitive and selective MEK1 and MEK2 inhibitor, with IC50s of 72 nM and 58 nM, respectively. U0126 is an autophagy and mitophagy inhibitor .
    U0126
  • HY-10162
    Olaparib
    175+ Cited Publications

    AZD2281; KU0059436

    PARP Autophagy Mitophagy Cancer
    Olaparib (AZD2281; KU0059436) is a potent and orally active PARP inhibitor with IC50s of 5 and 1 nM for PARP1 and PARP2, respectively. Olaparib is an autophagy and mitophagy activator .
    Olaparib
  • HY-N0109
    Salidroside
    15+ Cited Publications

    Rhodioloside

    mTOR Apoptosis Prolyl Endopeptidase (PREP) Cancer
    Salidroside (Rhodioloside) is a prolyl endopeptidase inhibitor. Salidroside alleviates cachexia symptoms in mouse models of cancer cachexia via activating mTOR signalling. Salidroside protects dopaminergic neurons by enhancing PINK1/Parkin-mediated mitophagy.
    Salidroside
  • HY-12031
    U0126-EtOH
    320+ Cited Publications

    MEK Autophagy Mitophagy Influenza Virus Cancer
    U0126 (U0126-EtOH) is a potent, non-ATP competitive and selective MEK1 and MEK2 inhibitor, with IC50s of 72 nM and 58 nM, respectively. U0126 is an autophagy and mitophagy inhibitor .
    U0126-EtOH
  • HY-N0484
    Liensinine
    5+ Cited Publications

    Autophagy Mitophagy Apoptosis Cardiovascular Disease Cancer
    Liensinine is an autophagy/mitophagy inhibitor. Liensinine, a major isoquinoline alkaloid, extracted from the seed embryo of Nelumbo nucifera Gaertn, has a wide range of biological activities, including anti-arrhythmias, anti-hypertension, anti-pulmonary fibrosis, relaxation on vascular smooth muscle, etc .
    Liensinine
  • HY-10162S1

    AZD2281-d8; KU0059436-d8

    PARP Autophagy Mitophagy Cancer
    Olaparib-d8 is the deuterium labeled Olaparib (AZD2281). Olaparib is a potent and orally active PARP inhibitor with IC50s of 5 and 1 nM for PARP1 and PARP2, respectively. Olaparib is an autophagy and mitophagy activator[1][2][3][4].
    Olaparib-d8
  • HY-10162S3

    AZD2281-d4-1; KU0059436-d4-1

    Isotope-Labeled Compounds PARP Autophagy Mitophagy Cancer
    Olaparib-d4-1 is the deuterium labeled Olaparib. Olaparib (AZD2281; KU0059436) is a potent and orally active PARP inhibitor with IC50s of 5 and 1 nM for PARP1 and PARP2, respectively. Olaparib is an autophagy and mitophagy activator[1][2][3][4].
    Olaparib-d4-1
  • HY-50856
    Ruxolitinib
    110+ Cited Publications

    INCB18424

    JAK Autophagy Mitophagy Apoptosis Cancer
    Ruxolitinib (INCB18424) is a potent and selective JAK1/2 inhibitor with IC50s of 3.3 nM and 2.8 nM in cell-free assays, and has 130-fold selectivity for JAK1/2 over JAK3 . Ruxolitinib induces autophagy and kills tumor cells through toxic mitophagy .
    Ruxolitinib
  • HY-16592
    Brefeldin A
    50+ Cited Publications

    BFA; Cyanein; Decumbin

    Autophagy CRISPR/Cas9 Mitophagy HSV Antibiotic Bacterial Infection Cancer
    Brefeldin A (BFA) is a lactone antibiotic and a specific inhibitor of protein trafficking. Brefeldin A blocks the transport of secreted and membrane proteins from endoplasmic reticulum to Golgi apparatus . Brefeldin A is also an autophagy and mitophagy inhibitor . Brefeldin A is a CRISPR/Cas9 activator . Brefeldin A inhibits HSV-1 and has anti-cancer activity .
    Brefeldin A
  • HY-N0109R

    Rhodioloside (Standard)

    Prolyl Endopeptidase (PREP) mTOR Apoptosis Cancer
    Salidroside (Standard) is the analytical standard of Salidroside. This product is intended for research and analytical applications. Salidroside (Rhodioloside) is a prolyl endopeptidase inhibitor. Salidroside alleviates cachexia symptoms in mouse models of cancer cachexia via activating mTOR signalling. Salidroside protects dopaminergic neurons by enhancing PINK1/Parkin-mediated mitophagy .
    Salidroside (Standard)
  • HY-160019

    Deubiquitinase Mitophagy Neurological Disease
    MTX115325 (Example 1) is an orally active, brain-penetrating USP30 inhibitor (IC50=12 nM) with neuroprotective activity. MTX115325 increases ubiquitination (EC50=32 nM) of the mitochondrial outer membrane protein TOM20 (a USP30 substrate), increasing mitophagy. MTX115325 prevents dopaminergic neuron loss and preserves striatal dopamine .
    MTX115325
  • HY-N0485
    Liensinine Diperchlorate
    5+ Cited Publications

    Autophagy Mitophagy Cardiovascular Disease
    Liensinine Diperchlor​ate is a major isoquinoline alkaloid, extracted from the seed embryo of Nelumbo nucifera Gaertn. Liensinine Diperchlor​ate inhibits late-stage autophagy/mitophagy through blocking autophagosome-lysosome fusion. Liensinine Diperchlor​ate has a wide range of biological activities, including anti-arrhythmias, anti-hypertension, anti-pulmonary fibrosis, relaxation on vascular smooth muscle, etc .
    Liensinine Diperchlorate
  • HY-150636

    Autophagy Apoptosis Cancer
    Autophagy-IN-1 is a potent autophagy/mitophagy inhibitor, acts by selectively increasing the autophagic flux while blocking the autophagosome-lysosome fusion in cancer cells. Autophagy-IN-1 can induce apoptosis and cell cycle arrest. Autophagy-IN-1 significantly inhibits tumor growth in an HCT116 xenograft mouse model and with low toxicity. Autophagy-IN-1 can be used for researching colorectal cancer .
    Autophagy-IN-1
  • HY-13417S

    Acadesine-13C2,15N; AICA Riboside-13C2,15N

    Isotope-Labeled Compounds Others
    AICAR- 13C2, 15N (Acadesine- 13C2, 15N; AICA Riboside- 13C2, 15N)is the 13C and 15N labeledAICAR(HY-13417) . AICAR (Acadesine) is an adenosine analog and a AMPK activator. AICAR regulates the glucose and lipid metabolism, and inhibits proinflammatory cytokines and iNOS production. AICAR is also an autophagy, YAP and mitophagy inhibitor .
    AICAR-13C2,15N
  • HY-15597
    Salinomycin
    20+ Cited Publications

    Procoxacin

    Bacterial Wnt β-catenin Mitophagy Autophagy Apoptosis Antibiotic Parasite Cancer
    Salinomycin (Procoxacin), a polyether potassium ionophore antibiotic, selectively inhibits the growth of gram-positive bacteria. Salinomycin is a potent inhibitor of Wnt/β-catenin signaling, blocks Wnt-induced LRP6 phosphorylation. Salinomycin (Procoxacin) shows selective activity against human cancer stem cells .
    Salinomycin
  • HY-N9182

    Physalien

    Adiponectin Receptor P2X Receptor Autophagy Inflammation/Immunology
    Zeaxanthin dipalmitate (Physalien) is a wolfberry-derived carotenoid, has anti-inflammatory and anti-oxidative stress effects. Zeaxanthin dipalmitate directly interact with p2X7 receptor (Kd=81.2 nM) and adiponectin receptor 1 (AdipoR1; Kd=533 nM) in a positive dose-dependent manner. Zeaxanthin dipalmitate restores mitochondrial autophagy functions suppressed by ethanol intoxication. Zeaxanthin dipalmitate can be used in the research of alcoholic fatty liver disease (AFLD) and retinitis pigmentosa (RP) .
    Zeaxanthin dipalmitate
  • HY-10256A
    Adezmapimod hydrochloride
    Maximum Cited Publications
    392 Publications Verification

    SB 203580 hydrochloride; RWJ 64809 hydrochloride

    Organoid p38 MAPK Autophagy Mitophagy Inflammation/Immunology Cancer
    Adezmapimod (SB 203580) hydrochloride is a selective and ATP-competitive p38 MAPK inhibitor with IC50s of 50 nM and 500 nM for SAPK2a/p38 and SAPK2b/p38β2, respectively. Adezmapimod hydrochloride inhibits LCK, GSK3β and PKBα with IC50s of 100-500-fold higher than that for SAPK2a/p38. Adezmapimod hydrochloride is an autophagy and mitophagy activator .
    Adezmapimod hydrochloride
  • HY-10256
    Adezmapimod
    Maximum Cited Publications
    392 Publications Verification

    SB 203580; RWJ 64809

    Organoid p38 MAPK Autophagy Mitophagy Inflammation/Immunology Cancer
    Adezmapimod (SB 203580) is a selective and ATP-competitive p38 MAPK inhibitor with IC50s of 50 nM and 500 nM for SAPK2a/p38 and SAPK2b/p38β2, respectively. Adezmapimod inhibits LCK, GSK3β and PKBα with IC50s of 100-500-fold higher than that for SAPK2a/p38. Adezmapimod does not disrupt JNK activity and is an autophagy and mitophagy activator .
    Adezmapimod